Prospective evaluation of KARSARC -a gene expression-based risk classifier for patients with soft tissue sarcomas treated with pazopanib
Research area:
Rare disease
Disease:
Intervention:
Phase:
Related news
TYSABRI gains market approval
Keytruda receives another breakthrough designation
